TARGETING IL-23: INSIGHTS INTO THE PATHOGENESIS AND THE TREATMENT OF PSORIASIS

Therapeutic experience strongly supports the use of TNF antagonists as important modalities in the treatment of psoriatic arthritis and plaque psoriasis. Studies with anti-IL-12/23 therapeutic agents, which act in different steps of the psoriatic inflammatory cascade, have also shown demonstrable ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Hermenio Cavalcante, Kimball, Alexandra Boer
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2010
Materias:
IJD Symposium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887523/
https://www.ncbi.nlm.nih.gov/pubmed/20606888
http://dx.doi.org/10.4103/0019-5154.62760
Descripción
Sumario:Therapeutic experience strongly supports the use of TNF antagonists as important modalities in the treatment of psoriatic arthritis and plaque psoriasis. Studies with anti-IL-12/23 therapeutic agents, which act in different steps of the psoriatic inflammatory cascade, have also shown demonstrable efficacy. Here, we discuss this approach and its potential within the armamentarium for the treatment of psoriasis. Evidences that the selective blocking of IL-23 may be effective and safe therapy are also addressed.

Ejemplares similares